PubRank

Serge Koscielny

Author PubWeight™ 65.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005 17.75
2 False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 2005 3.83
3 Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2013 2.06
4 The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007 1.83
5 Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology 2010 1.51
6 Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010 1.42
7 The efficacy of premixed nitrous oxide and oxygen for fiberoptic bronchoscopy in pediatric patients: a randomized, double-blind, controlled study. Chest 2004 1.40
8 Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2013 1.35
9 Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008 1.21
10 Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol 2012 1.15
11 Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. Eur J Radiol 2012 1.12
12 MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2008 1.01
13 Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 2011 1.00
14 Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. Invest Radiol 2014 0.99
15 Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study. Invest Radiol 2012 0.99
16 High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 2004 0.99
17 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci 2010 0.96
18 Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging 2006 0.96
19 Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs 2010 0.95
20 Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007 0.94
21 Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 2004 0.85
22 Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 2007 0.85
23 Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Haematologica 2011 0.84
24 Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl 2012 0.84
25 Modification of behavior with 50% nitrous oxide/oxygen conscious sedation over repeated visits for dental treatment a 3-year prospective study. J Clin Psychopharmacol 2006 0.84
26 Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 2005 0.84
27 Effect of formaldehyde on asthmatic response to inhaled allergen challenge. Environ Health Perspect 2006 0.84
28 High-frequency sonography and color Doppler in the management of pigmented skin lesions. Ultrasound Med Biol 2003 0.84
29 Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 2008 0.83
30 Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas. Int J Radiat Oncol Biol Phys 2005 0.83
31 Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas. AJR Am J Roentgenol 2002 0.83
32 Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Leuk Lymphoma 2008 0.83
33 Repair of ionizing radiation-induced DNA damage and risk of second cancer in childhood cancer survivors. Carcinogenesis 2014 0.81
34 A prospective multicentric trial for effectiveness and tolerance of a N2O/O2 premix used as a sedative drug. J Clin Psychopharmacol 2004 0.81
35 Multidimensionality of microarrays: statistical challenges and (im)possible solutions. Mol Oncol 2011 0.80
36 Validation of microarray data by quantitative reverse-transcriptase polymerase chain reaction. J Clin Oncol 2005 0.80
37 Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle 2008 0.79
38 Sedation with 50% nitrous oxide/oxygen for outpatient dental treatment in individuals with intellectual disability. Dev Med Child Neurol 2007 0.78
39 Long-term mortality in a cohort study of 6,800 French breast cancer patients treated between 1954 and 1983. Acta Oncol 2008 0.78
40 On clonogenic tumour cells and metastasis-forming cells. Nat Rev Cancer 2008 0.77
41 A clinical trial of efficacy and safety of inhalation sedation with a 50% nitrous oxide/oxygen premix (Kalinox™) in general practice. Clin Oral Investig 2011 0.77
42 Repeated nitrogen dioxide exposures and eosinophilic airway inflammation in asthmatics: a randomized crossover study. Environ Health Perspect 2014 0.77
43 Therapy-related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients. Br J Haematol 2003 0.77
44 Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs 2010 0.77
45 Parallel progression of tumour and metastases. Nat Rev Cancer 2010 0.76
46 BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma. PLoS One 2013 0.76
47 Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer. Curr Opin Oncol 2014 0.76
48 TGR analysis in phase I clinical trials--response. Clin Cancer Res 2014 0.75
49 Clinical usefulness of microarrays for cancer prognosis in 2010--letter. Clin Cancer Res 2010 0.75
50 Study of Intrapatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography. Invest Radiol 2017 0.75
51 Loco-regional recurrence risk and post-mastectomy radiotherapy in breast cancer. Radiother Oncol 2010 0.75
52 [Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)]. Bull Cancer 2008 0.75
53 Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). Crit Rev Oncol Hematol 2007 0.75
54 Decision making process in oncology practice: is the information available and what should it consist of? Crit Rev Oncol Hematol 2005 0.75